MaxCyte Inc
MXCT2.045USD
+0.005+0.25%
交易中 （美东）报价延迟15分钟
217.41M总市值
亏损市盈率 TTM
关于 MaxCyte Inc 公司
MaxCyte, Inc. 是一家专注于细胞工程的公司，提供解决方案以促进细胞疗法的发现、开发和商业化。该公司利用其细胞工程技术平台来支持从事细胞疗法的生物技术和制药公司客户的计划。其 ExPERT 平台基于其流式电穿孔技术，旨在支持不断扩大的细胞疗法市场，并可用于整个细胞疗法领域，从发现和开发到下一代细胞药物的商业化。ExPERT 系列产品包括四种仪器，即 ATx、STx、GTx 和 VLx；一系列专有相关处理组件或一次性用品；以及软件协议，所有这些都由全球知识产权组合支持。该公司还通过 ONE-seq 和 GUIDE-seq 平台为基因编辑提供全面的脱靶风险评估解决方案。
公司简介
公司代码MXCT
公司名称MaxCyte Inc
上市日期Mar 29, 2016
CEOMr. Maher Masoud, J.D.
员工数量114
证券类型Ordinary Share
年结日Mar 29
公司地址9713 Key West Avenue,
城市ROCKVILLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编20850
电话13015175556
网址https://www.maxcyte.com/
公司代码MXCT
上市日期Mar 29, 2016
CEOMr. Maher Masoud, J.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ali Soleymannezhad
Mr. Ali Soleymannezhad
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
业务USD
名称
营收
占比
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
地区USD
名称
营收
占比
Inside the United States
8.03M
77.32%
Outside the United States
2.36M
22.68%
业务
地区
业务USD
名称
营收
占比
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
股东统计
更新时间: 7月24日 周四
更新时间: 7月24日 周四
持股股东
股东类型
持股股东
持股股东
占比
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
持股股东
持股股东
占比
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
24.01%
Investment Advisor
23.62%
Hedge Fund
14.89%
Private Equity
4.83%
Research Firm
3.90%
Individual Investor
1.42%
Bank and Trust
0.71%
Pension Fund
0.16%
Insurance Company
0.03%
Other
26.41%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
294
78.23M
73.51%
-18.98M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
2023Q1
275
80.19M
77.98%
-11.53M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cadian Capital Management LP
10.03M
9.42%
+683.30K
+7.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.41M
6.97%
+63.83K
+0.87%
Mar 31, 2025
The Vanguard Group, Inc.
5.57M
5.23%
+135.98K
+2.50%
Mar 31, 2025
Vitruvian Partners LLP
5.04M
4.74%
--
--
Mar 31, 2025
Mirabella Financial Services LLP
3.70M
3.48%
--
--
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
3.55M
3.34%
-547.43K
-13.36%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.44M
3.23%
+3.16M
+1117.21%
Mar 31, 2025
Mudita Advisors LLP
3.33M
3.13%
+105.03K
+3.26%
Mar 31, 2025
River Global Investors LLP
3.25M
3.06%
+1.19M
+57.73%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.75M
2.59%
-180.54K
-6.15%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.41%
iShares Micro-Cap ETF
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
